UBS Group AG Buys 113,499 Shares of Capricor Therapeutics, Inc. $CAPR

UBS Group AG lifted its stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 91.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 238,216 shares of the biotechnology company’s stock after acquiring an additional 113,499 shares during the period. UBS Group AG’s holdings in Capricor Therapeutics were worth $6,875,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in Capricor Therapeutics in the third quarter valued at $1,555,000. Pier Capital LLC grew its position in Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after purchasing an additional 128,837 shares in the last quarter. AlphaQuest LLC grew its position in Capricor Therapeutics by 396.2% in the third quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 23,974 shares in the last quarter. Vanguard Group Inc. grew its position in Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares in the last quarter. Finally, Parkside Financial Bank & Trust bought a new position in Capricor Therapeutics in the third quarter valued at $36,000. Institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

CAPR has been the subject of a number of analyst reports. B. Riley Financial raised their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Roth Mkm reiterated a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a research note on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.36.

Insider Buying and Selling

In other news, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the sale, the director owned 7,529 shares in the company, valued at approximately $240,928. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is currently owned by corporate insiders.

Capricor Therapeutics Stock Down 3.9%

CAPR stock opened at $26.92 on Wednesday. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37. The firm has a market cap of $1.56 billion, a P/E ratio of -11.60 and a beta of 0.48. The company’s 50-day moving average price is $31.88 and its two-hundred day moving average price is $24.65.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities analysts predict that Capricor Therapeutics, Inc. will post -0.75 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.